Sample cardiovascular prevention report
Enter your lab values, imaging, and the questions you want addressed, and the agent produces a downloadable report like the one below — a plain-language interpretation, your risk-based targets, your 10- and 30-year risk, and the specific questions worth raising with a cardiologist. Book at the end, and it's already in your chart. (Example below — synthetic data, not a real patient.)
This is an example. The agent's summary is AI-generated — not a medical diagnosis and not a substitute for evaluation by a clinician. Your real report is built from what you enter.
Overall assessment
Your LDL-C 154 and ApoB 133 mg/dL (both target below 100) are above target — closing that gap is the main thing your cardiologist will work on.
Your non-HDL-C of 185 mg/dL is above the target of 130 as well — in line with the elevated LDL and ApoB.
Your Lp(a) of 315 nmol/L is elevated. It's largely inherited and isn't lowered by statins or diet, so it changes how aggressively your other risks are treated rather than being a target of its own.
Your advanced panel adds detail beyond the standard lipids: an elevated LDL particle number, a low omega-3 index, and a cluster of endothelial-inflammation markers (Lp-PLA2, TMAO, MPO) above their reference ranges. These are associated with risk but are not established treatment targets — part of the visit is deciding which are worth acting on and which are noise, anchored to your imaging and absolute risk.
Your blood pressure of 135/85 is above the optimal range (goal under 120/80), which adds to your overall cardiovascular risk.
Lipids & your targets
| Marker | Current | Your target | Status |
|---|---|---|---|
| LDL-C | 154 mg/dL | below 100 mg/dL | above target |
| ApoB | 133 mg/dL | below 100 mg/dL | above target |
| non-HDL-C | 185 mg/dL | below 130 mg/dL | above target |
Targets are set from your overall risk — not a population average — which is why they may differ from a lab report's reference range.
Your cardiovascular risk
Calculated with PREVENT (American Heart Association); raised by South Asian ancestry.
Other results
Your questions, with the guidelines that bear on them.
1. Given a PREVENT-ASCVD 10-year risk of 2.2% (borderline range: 3% to <5% begins where statin initiation becomes a reasonable consideration [1]), an LDL-C of 154 mg/dL (ref <99 mg/dL; target <100 mg/dL), an ApoB of 133 mg/dL (ref <99 mg/dL; target <100 mg/dL), an Lp(a) of 315 nmol/L (ref <75 nmol/L), and South Asian ancestry as a risk enhancer — how do these factors weigh into the benefit–risk discussion [2] about whether to initiate statin therapy for primary prevention?
In your words: "Should I be on a statin?"
References: [1] ACC HCH 2026, p47 — jacc.org/doi/10.1016/j.jacc.2025.11.016; [2] ACC HCH 2026, p44 — jacc.org/doi/10.1016/j.jacc.2025.11.016
2. Given an LDL particle number of 1,580 nmol/L (discordantly high relative to LDL-C), a low omega-3 index (4.1%), and elevated endothelial-inflammation markers (Lp-PLA2 195 nmol/min/mL, TMAO 6.2 µmol/L, MPO 520 pmol/L) — these carry population-level associations with cardiovascular risk but limited or inconclusive interventional evidence. Which, if any, warrant action (diet and gut changes for TMAO; EPA for the omega-3 index) versus watchful non-escalation, anchored to my imaging and absolute risk?
In your words: "My advanced markers are flagged — TMAO, inflammation, particle number. Which actually matter, and which am I chasing?"
Evidence tier: association-level (cohort / cross-sectional); interventional data limited or inconclusive — read as calibrated equipoise, not a treatment target.
Book a cardiologist who can order tests and prescribe — usually same or next day. Everything you entered is already in your chart.